Description
GLP-1S (Sema) is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor. Novo Nordisk describes sema as supporting glucose-related pathways by stimulating insulin secretion in a glucose-dependent manner, lowering glucagon secretion, and causing a minor delay in gastric emptying. Its strong recognition in GLP-1 research has made it one of the most prominent compounds in this category. This makes it a clear, modern option for product copy tied to GLP-1 pathway research.
Reviews
There are no reviews yet.